Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose ICG for Biliary Imaging
NCT04942665Phase 2Completed
- Sponsor
- University of Florida
- Start
- Sep 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of indocyanine green in cholecystitis, hepatocellular carcinoma (HCC) and liver metastases (2 arms), sponsored by University of Florida. Primary endpoint: Quantitative Assessment - Bile Duct-to-liver Fluorescence Intensity Ratio. Started Sep 2021; status: completed.
02
Drugs
indocyanine green
03
Conditions
cholecystitishepatocellular carcinoma (HCC)liver metastases
Beyond the preview
Go deeper on NCT04942665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04942665.